Navigation Links
Kips Bay Medical, Inc. Announces Pricing of its Initial Public Offering of Common Stock
Date:2/10/2011

MINNEAPOLIS, Feb. 10, 2011 /PRNewswire/ -- Kips Bay Medical, Inc. (Nasdaq: KIPS) announced today the pricing of the Company's initial public offering of 2,062,500 shares of its common stock at a price of $8.00 per share.  The shares are expected to begin trading on February 11, 2011 on the NASDAQ Global Market under the ticker symbol "KIPS."  The closing of the offering is scheduled to take place on February 16, 2011.  The Company has granted the underwriters a 45-day option to purchase up to an additional 309,375 shares of common stock at the initial public offering price to cover over-allotments, if any.  The Company intends to use the proceeds of the offering to fund the process of seeking regulatory approval to market its external saphenous vein support technology, or eSVS MESH, in the United States, to fund the development and testing of additional applications of its eSVS MESH, to fund certain milestone payments related to acquired intellectual property, and the remainder, if any, for working capital and general corporate purposes.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM), is acting as sole book-running manager of the offering and Newbridge Securities Corporation, Caris & Company and Chardan Capital Markets, LLC are acting as co-managers.  This offering is being made solely by means of a prospectus.  Copies of the final prospectus relating to the offering, when available, may be obtained from Rodman & Renshaw, LLC at 1251 Avenue of the Americas, New York, NY 10020, via telephone at (212) 430-1710, via email to prospectus@rodm.com or by visiting the U.S. Securities and Exchange Commission website at http://www.sec.gov.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 10, 2011. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Kips Bay Medical, Inc:  Kips Bay Medical, Inc., founded in 2007 and headquartered in Minneapolis, Minnesota, is a development stage medical device company focused on developing, manufacturing and commercializing its eSVS MESH for use in coronary artery bypass grafting surgery.  Additional information about Kips Bay Medical, Inc. can be found at www.kipsbaymedical.com. Contact:Kips Bay Medical, Inc.Manny Villafana, Chairman and Chief Executive OfficerScott Kellen, Chief Financial OfficerPhone: +1-763-235-3540Email: manny.villafana@kipsbaymedical.com
'/>"/>

SOURCE Kips Bay Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cayenne Medical, Inc. Appoints David B. Springer President & CEO
2. Frost & Sullivan Recognizes Cohera Medical, Inc.® for Developing TissuGlu®, Its Pioneering Surgical Adhesive That Is Strong, Easy-To-Use, Biocompatible and Resorbable
3. Nonin Medical, Inc. Launches New WristOx2™, Model 3150 in U.S. and Canada
4. Kevin Banion Named CEO of Progressive Medical, Inc.
5. Solta Medical, Inc. Appoints Thomas J. Yorkey, Ph.D. to Vice President of Research & Development
6. BioDrain Medical, Inc. Is Eligible for Trading on the OTCBB, Notice of Allowance on Canadian Patent Application
7. Audax Medical, Inc. Receives Therapeutic Discovery Grant for Development of Regenerative Bone Material
8. Audax Medical, Inc. Secures Exclusive Rights to Novel Osteobiologic Nanotechnology
9. Prescient Medical, Inc. Presenting at the 5th Annual Canaccord Genuity Cardiovascular Conference
10. Cayenne Medical, Inc. Reaches 50,000 Implant Milestone
11. A Platform Technology to Address Bioterrorism Released by Aethlon Medical, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 24, 2017  Eli Lilly and Company (NYSE: ... invest $850 million in its U.S. operations in ... U.S. enterprise, including research laboratories, manufacturing sites, and ... driven by demand for Lilly products, as well ... development targeting cancer, pain, diabetes and other unmet ...
(Date:3/24/2017)... YORK and GENEVA , ... announced on World Tuberculosis Day revitalizes efforts to develop ... On World Tuberculosis Day, TB Alliance and ... for the clinical development of sutezolid, an antibiotic drug ... sublicense pertains to the development of sutezolid in combination ...
(Date:3/23/2017)... PUNE, India , March 23, 2017 ... are growing ageing population, increasing diabetic population, accelerating economic growth ... developments of this industry are higher life expectancy of ESRD ... potential in emerging markets. However, the expansion of the market ... ...
Breaking Medicine Technology:
(Date:3/24/2017)... , ... March 24, 2017 , ... ... which will spark a conversation on the current obstacles facing infection prevention and ... completely preventable deaths caused by these infections. , The print component of ...
(Date:3/24/2017)... ... ... Texas Physical Therapy Specialists (TexPTS) is pleased to announce the opening ... is the group’s 7th location in San Antonio and 23rd in Texas. Dr. ... from the clinic, which opened March 22, 2017. , The team of ...
(Date:3/24/2017)... Pittsburgh, PA (PRWEB) , ... March 24, 2017 ... ... the Oncology Nursing Society (ONS) wanted to create a communications platform that positions ... realize this goal, Elliance and ONS reinvented their online publication as an always-on, ...
(Date:3/24/2017)... ... 24, 2017 , ... Gastro Health (“GH”) ( http://www.gastrohealth.com ... for colonoscopy at the HyGIeaCare® Center that is to be located adjacent to ... , The HyGIeaCare® Prep, cleared by the U.S. Food and Drug Administration (FDA), ...
(Date:3/24/2017)... ... 24, 2017 , ... “Vintage and Harvest A Cultivation of Christian Love” is ... residing in North Carolina with his wife, Anna Marie. He and his wife are ... David is also the author of “Shadow and Substance.” , “Love, the agape kind, ...
Breaking Medicine News(10 mins):